Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Leslie Williams

Nurse Practitioner Winston Salem, NC Nurse Practitioner

NPI 1992053854 CMS profile 10518331

3001 Lyndhurst Ave, Winston Salem, NC 27103

Open in the dashboard

General payments

$6,629

357 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leslie Williams of Winston Salem, NC is reported in the CMS Open Payments database as having received $6,629 across 357 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,363 69
2024 General $1,652 90
2023 General $1,100 59
2022 General $1,199 65
2021 General $1,316 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leslie Williams
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Leslie Williams were reported at $1,363. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Leslie Williams Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,316 $135 $40–$426 $132
2022 $1,199 $152 $48–$470 $149
2023 $1,100 $166 $54–$529 $160
2024 $1,652 $173 $55–$556 $164
2025 $1,363 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $1,006 49 payments
  2. AstraZeneca Pharmaceuticals LP $916 52 payments
  3. GlaxoSmithKline, LLC. $831 60 payments
  4. United Therapeutics Corporation $456 24 payments
  5. Regeneron Healthcare Solutions, Inc. $438 18 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $330 16 payments
  7. Genzyme Corporation $232 9 payments
  8. Mylan Specialty L.P. $205 11 payments
  9. Merck Sharp & Dohme Corporation $193 12 payments
  10. Baxter Healthcare $177 8 payments
  11. Other $1,845 98 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,471 355 payments
  2. Education $158 2 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $537 42 payments
  2. OFEV Respiratory $532 28 payments
  3. SPIRIVA RESPIMAT $417 22 payments
  4. DUPIXENT Inflammation And Immunology $381 15 payments
  5. BREZTRI $350 24 payments
  6. NUCALA $344 23 payments
  7. OFEV Respiratory $281 14 payments
  8. DUPIXENT Immunology $268 9 payments
  9. YUPELRI $267 14 payments
  10. TYVASO $250 12 payments
  11. Other $4,112 225 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

2,163

Median for Nurse Practitioner: 389

Drug cost

$813,923

Median for Nurse Practitioner: $21,885

Branded share of claims

74.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 507 $391,894
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 120 $109,249
Breo Ellipta Fluticasone/Vilanterol Brand 188 $97,153
Spiriva Respimat Tiotropium Bromide Brand 111 $71,186
Symbicort Budesonide/Formoterol Fumarate Brand 97 $30,153
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 51 $25,187
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 41 $20,334
Incruse Ellipta Umeclidinium Bromide Brand 35 $14,585
Arnuity Ellipta Fluticasone Furoate Brand 45 $13,390
Albuterol Sulfate Hfa Albuterol Sulfate Brand 249 $7,606

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $274
  • SANOFI-AVENTIS U.S. LLC $60
  • GENZYME CORPORATION $19
$353 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $165
$165 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $147
$147 — —
TYVASO
  • United Therapeutics Corporation $129
$129 — —
YUPELRI
  • Mylan Specialty L.P. $73
$73 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

357 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record